AnalystsAndreas ArgyridesAndreas Argyrides's Stock Forecasts
AnalystsAndreas Argyrides
Sectors:
Analyst Ranking
Top 8%
#389 out of 5277 analysts
Average Return
+20.08%
Win Rate
51%58 out of 113
Risk vs Reward
Poor
Good
Andreas Argyrides's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Aquestive Therapeutics IncAQST | +502.47% | $0.81 | $4.88 | 2023-03-08 - 2024-03-08 | Buy |
Regulus Therapeutics IncRGLS | +429.87% | $1.54 | $8.16 | 2024-08-13 - 2025-06-24 | Buy |
Ars Pharmaceuticals IncSPRY | +315.25% | $4.00 | $16.61 | 2023-11-12 - 2024-11-12 | Buy |
Ars Pharmaceuticals IncSPRY | +302.45% | $3.67 | $14.77 | 2023-09-20 - 2024-09-20 | Buy |
Aquestive Therapeutics IncAQST | +240.00% | $1.40 | $4.76 | 2023-10-09 - 2024-10-09 | Buy |
Andreas Argyrides Analyst Color
Get additional color on Andreas Argyrides's coverage of popular stocks
Andreas Argyrides's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Opus Genetics IncIRD | 1 | Buy | $10.00 | +93.05% | Initiates Coverage On | 2 months ago |
Liquidia CorpLQDA | 7 | Sell | $19.00 | -66.43% | Maintains | 2 months ago |
Gossamer Bio IncGOSS | 9 | Buy | $3.00 | +779.77% | Maintains | 2 months ago |
United Therapeutics CorpUTHR | 2 | Buy | $600.00 | +3.14% | Maintains | 3 months ago |
Moonlake ImmunotherapeuticsMLTX | 15 | Buy | $35.00 | +92.41% | Maintains | 3 months ago |
Evommune IncEVMN | 1 | Buy | $42.00 | +85.10% | Initiates Coverage On | 4 months ago |
Dyne Therapeutics IncDYN | 5 | Buy | $40.00 | +117.75% | Upgrades | 5 months ago |
Savara IncSVRA | 2 | Buy | $9.00 | +77.17% | Maintains | 6 months ago |
Keros Therapeutics IncKROS | 9 | Buy | $27.00 | +131.76% | Reiterates | 6 months ago |
Monopar TherapeuticsMNPR | 2 | Buy | $115.00 | +87.45% | Maintains | 7 months ago |
Larimar Therapeutics IncLRMR | 2 | Buy | $21.00 | +408.47% | Maintains | 7 months ago |
Benitec Biopharma IncBNTC | 2 | Buy | $29.00 | +144.93% | Maintains | 8 months ago |
Kala Bio IncKALA | 2 | Buy | $1,650.00 | +52,784.62% | Maintains | 8 months ago |
Mannkind CorpMNKD | 2 | Buy | $15.00 | +357.32% | Maintains | 8 months ago |
Abeona Therapeutics IncABEO | 2 | Buy | $20.00 | +252.11% | Maintains | 9 months ago |
Harmony Biosciences Holdings IncHRMY | 1 | Buy | $61.00 | +102.32% | Assumes | a year ago |
Aquestive Therapeutics IncAQST | 5 | Buy | $7.00 | +68.27% | Assumes | a year ago |
Inflarx NvIFRX | 2 | Buy | $3.00 | +23.46% | Maintains | a year ago |
Rani Therapeutics Holdings IncRANI | 5 | Buy | $4.00 | +263.64% | Maintains | a year ago |
Korro Bio IncKRRO | 1 | Buy | $90.00 | +702.14% | Maintains | a year ago |
Proqr Therapeutics NvPRQR | 1 | Buy | $9.00 | +462.50% | Maintains | a year ago |
Ascendis Pharma AASND | 9 | Buy | $181.00 | N/A | Reiterates | a year ago |
Regulus Therapeutics IncRGLS | 1 | Buy | $7.00 | N/A | Reiterates | 2 years ago |
Clearside Biomedical IncCLSDQ | 1 | Buy | $75.00 | N/A | Initiates Coverage On | 2 years ago |
Ars Pharmaceuticals IncSPRY | 9 | Buy | $19.00 | N/A | Reiterates | 2 years ago |
Oculis Holding AgOCS | 3 | Buy | $29.00 | N/A | Reiterates | 2 years ago |
Regenxbio IncRGNX | 4 | Hold | $21.00 | N/A | Reiterates | 2 years ago |
Sarepta Therapeutics IncSRPT | 4 | Buy | $224.00 | N/A | Reiterates | 2 years ago |
Pacira Biosciences IncPCRX | 2 | Buy | $57.00 | N/A | Reiterates | 2 years ago |
Immunic IncIMUX | 3 | Buy | $70.00 | N/A | Maintains | 3 years ago |
Sangamo Therapeutics IncSGMO | 3 | Buy | $10.00 | N/A | Maintains | 3 years ago |
Biomarin Pharmaceutical IncBMRN | 6 | Hold | $70.00 | N/A | Maintains | 3 years ago |
Unity Biotechnology IncUNBX | 4 | Hold | $2.00 | N/A | Downgrades | 3 years ago |
Albireo Pharma IncALBO | 2 | Hold | $42.00 | N/A | Downgrades | 3 years ago |
Global Blood Therapeutics IncGBT | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.